Caution advised in interpretation of US FDA risk classification for dermatological medications during pregnancy

Dermatology Online Journal

Volumn 18, Issue 10, 2012, Pages 15-

  Wong, Jillian W ^a,b   Heller, Misha M ^c,d   Murase, Jenny E ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c NONE

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CLOTRIMAZOLE; CORTICOSTEROID; DIPHENHYDRAMINE; ETANERCEPT; HYDROCORTISONE; IMIDAZOLE; INFLIXIMAB; NON PRESCRIPTION DRUG; NYSTATIN; PRESCRIPTION DRUG;

ALLERGY; ARTICLE; AUSTRALIA; CONGENITAL MALFORMATION; COUNSELING; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GENERAL ANESTHESIA; HUMAN; NAUSEA; NONHUMAN; ORGANOGENESIS; PATIENT EDUCATION; PRACTICE GUIDELINE; PREGNANCY; PRURITUS; PSORIASIS; RETROLENTAL FIBROPLASIA; RISK ASSESSMENT; SIDE EFFECT; TERATOGENICITY; UTERUS CONTRACTION; VOMITING; WOMEN'S HEALTH;

ABNORMALITIES, DRUG-INDUCED; DERMATOLOGIC AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; FETUS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84867910973     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Riley EH, Fuentes-Afflick E, Jackson RA, et al. Correlates of prescription drug use during pregnancy. J Womens Health (Larchmt). 2005;14:401-409. [PubMed]
2. Lee E, Maneno MK, Smith L, et al. National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf. 2006;15:537-545. [PubMed]
3. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191:398-407. [PubMed]
4. Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg L, Olsen J, Sorensen HT. Drug use in first pregnancy and lactation: a population-based survey among Danish women. The EUROMAP group. Eur J Clin Pharmacol. 1999;55:139-144. [PubMed]
5. Splinter MY, Sagraves R, Nightengale B, Rayburn WF. Prenatal use of medications by women giving birth at a university hospital. South Med J. 1997;90:498-502. [PubMed]
6. Rubin JD, Ferencz C, Loffredo C. Use of prescription and non-prescription drugs in pregnancy. The Baltimore-Washington Infant Study Group. J Clin Epidemiol. 1993;46:581-589. [PubMed]
7. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect. 1998;30:24-29, 46. [PubMed]
8. Boothby LA, Doering PL. FDA labeling system for drugs in pregnancy. Ann Pharmacother. 2001;35:1485-1489. [PubMed]
9. Charlton RA, Cunnington MC, de Vries CS, Weil JG. Data resources for investigating drug exposure during pregnancy and associated outcomes: the General Practice Research Database (GPRD) as an alternative to pregnancy registries. Drug Saf. 2008;31:39-51. [PubMed]
10. Webster WS, Freeman JA. Is this drug safe in pregnancy? Reprod Toxicol. 2001;15:619-629. [PubMed]
11. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338:1128-1137. [PubMed]
12. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf. 2000;23:245-253. [PubMed]
13. Sannerstedt R, Lundborg P, Danielsson BR, et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf. 1996;14:69-77. [PubMed]
14. Schaefer C, Peters PWJ, Miller RK. Drugs during pregnancy and lactation: treatment options and risk assessment. 2nd ed. Amsterdam; Boston: Elsevier Academic Press; 2007.